While tamoxifen use is associated with clear benefits in the treatment of hormone-sensitive breast cancer, it also exhibits partial oestrogen agonist activity that is associated with adverse events, ...
Phase 0 Clinical Trials in Oncology: An Exploratory Methodology for Constructing a Study With Patients Undergoing Surgery for Metastatic Disease Given that fulvestrant was, unexpectedly, only ...
Please provide your email address to receive an email when new articles are posted on . The combination of anastrozole and fulvestrant extended median survival of women with hormone-receptor–positive ...
Increasing the dose of fulvestrant from 250 mg to 500 mg improved median overall survival in women with locally advanced or metastatic estrogen receptor-positive breast cancer, according to updated ...
Hosted on MSN
AstraZeneca’s New Study on Capivasertib+Fulvestrant: A Potential Game-Changer in Breast Cancer Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)), AstraZeneca ((DE:ZEGA)) announced an update on their ongoing clinical study. Easily unpack a company's performance with ...
Results of the CONFIRM study presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium reveals that doubling the dose of fulvestrant to 500mg from 250mg can improve the overall survival ...
A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.The study found that combing two drugs that ...
SAN ANTONIO, Dec. 6, 2023 /PRNewswire/ -- MEDSIR today announced the results from the PARSIFAL-LONG study, a 5-year extended follow-up of the PARSIFAL study on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results